Indivior PLC (LON:INDV – Get Free Report) shares dropped 15.7% during trading on Thursday . The company traded as low as GBX 548.71 ($6.93) and last traded at GBX 732 ($9.25). Approximately 1,888,371 shares traded hands during mid-day trading, an increase of 166% from the average daily volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.97).
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 1,800 ($22.74) target price on shares of Indivior in a research note on Tuesday, December 17th.
Read Our Latest Research Report on INDV
Indivior Price Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Recommended Stories
- Five stocks we like better than Indivior
- Stock Market Sectors: What Are They and How Many Are There?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- DuPont’s Electronics Spinoff: The Start of Something Big
- 3 Ways To Invest In Coffee, Other Than Drinking It
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.